SCHEMBL2777568

SCHEMBL2777568

CCOC(=O)c1ncc2c(CC)noc2c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
MAPT P10636 2/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38
XBP1 P17861 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B10 Q99714 1/20 0.38
TLR9 Q9NR96 1/20 0.38
GABRA1 P14867 4/20 0.37
GABRG2 P18507 4/20 0.37
GABRB3 P28472 4/20 0.37
GABRA5 P31644 4/20 0.37
GABRA3 P34903 4/20 0.37
GABRA2 P47869 4/20 0.37
GABRA6 Q16445 3/20 0.37
TDP2 O95551 2/20 0.36
GABRP O00591 2/20 0.35
GABRD O14764 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2776420 0.79 ALDH1A1 (0.46) ALDH1A1MAPTMAPK1HSD17B10GABRA5
SCHEMBL2775027 0.78 CDC7 (0.44) ALDH1A1MAPK1NPSR1HSD17B10GABRA5
SCHEMBL2776306 0.77 ALDH1A1 (0.43) ALDH1A1MAPTNPC1MAPK1NPSR1
SCHEMBL2776184 0.77 TARBP2 (0.48) ALDH1A1MAPTNPC1HTTGABRA1
SCHEMBL2778422 0.76 ALDH1A1 (0.49) ALDH1A1MAPTNPC1TP53MAPK1
SCHEMBL2777919 0.76 MAPT (0.45) ALDH1A1MAPTTP53HTTNPSR1
SCHEMBL2776417 0.75 JAK2 (0.45) ALDH1A1MAPTTP53HSD17B10GABRA1
SCHEMBL30862696 0.73 TARBP2 (0.41) ALDH1A1MAPTNPC1TP53XBP1
SCHEMBL3661750 0.71 ALDH1A1 (0.41) ALDH1A1MAPTNPC1TP53MAPK1
SCHEMBL2777580 0.70 ALDH1A1 (0.40) ALDH1A1MAPTNPC1TP53XBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2227475-B1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN INC (US) 2014-02-19 EP disclosed
US-8269008-B2 Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions FIBROGEN, INC. (US) 2012-09-18 US disclosed
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2010-12-02 US disclosed
EP-2227475-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS Fibrogen, Inc. (US) 2010-09-15 EP disclosed
WO-2009073669-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS FIBROGEN, INC. (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100303928-A1 ISOXAZOLOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF HIF-MEDIATED CONDITIONS HIF1AN, HIF1A, EGLN2 ALDH1A1 219/4885MAPT 3874/4885NPC1 3806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.